ARWR

Arrowhead Pharmaceuticals (ARWR) posted first fiscal quarter 2026 revenue of $264 million. A key milestone was the approval of REDEMPLO, marking a commercial shift for the company and increasing its focus on therapy commercialization.

AI-generated: summaries written by AI from the linked sources. How we use AI